RxDoctor Payments Data

Angelo Santiago, MD

Neurology · Casper, WYNPI 1598792483

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 84 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations.

$1,629in general payments, 2019–2025

Across 84 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$387
  • Biogen$244
  • TG Therapeutics, Inc.$151
  • Lilly USA, LLC$121
  • Teva Pharmaceuticals USA, Inc.$97
  • Abbott$93
  • plus $536 from 14 others

What the payments were for

  • Food & beverage$1,60198%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few neurology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,063,558
Medicare patients
762
Services billed
155,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab11$127,701
Avonex (4 Pack)Interferon Beta-1a13$105,732
Aimovig AutoinjectorErenumab-Aooe47$40,051
QuliptaAtogepant27$32,957
KeppraLevetiracetam29$32,378
XcopriCenobamate25$30,818
LamictalLamotrigine13$20,657
Emgality PenGalcanezumab-Gnlm25$19,660
NeuproRotigotine13$11,022
Tiagabine Hcl27$9,800
Rufinamide12$7,862
Mycophenolate Mofetil27$4,795
Zonisamide116$4,492
Baclofen66$4,041
Acetazolamide17$3,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$244$105,73213 claims
AbbVieQulipta$387$32,95727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other neurology in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →